Codice QR

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)

Introduction: The combination of immune checkpoint inhibitors with chemotherapy is the standard treatment for extensive-stage (ES) SCLC. However, its safety for elderly patients is not fully validated. We evaluated the safety and efficacy of durvalumab plus carboplatin and etoposide in elderly patie...

Descrizione completa

Salvato in:
Autori principali: Hidenobu Ishii, MD, PhD, Koichi Azuma, MD, PhD, Yuta Yamanaka, MD, Hiroshige Yoshioka, MD, PhD, Yukihiro Toi, MD, Naoki Shingu, MD, Katsuhiko Naoki, MD, PhD, Masaki Okamoto, MD, PhD, Yuko Tsuchiya-Kawano, MD, PhD, Taishi Harada, MD, Hiroyuki Inoue, MD, PhD, Hiroshi Ishii, MD, PhD, Kazunori Tobino, MD, PhD, Chiho Nakashima, MD, PhD, Yoshifusa Koreeda, MD, Yasushi Hisamatsu, MD, Shinsuke Tsumura, MD, Takashi Inagaki, MD, Keiko Mizuno, MD, PhD, Takayuki Shimose, MMath, Isamu Okamoto, MD, PhD
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2025-07-01
Serie:JTO Clinical and Research Reports
Soggetti:
Small cell lung cancer
Durvalumab
Elderly
Immunotherapy
Accesso online:http://www.sciencedirect.com/science/article/pii/S2666364325000529
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi